Nike Kicks Off Multi-Year Innovation Cycle
11.4.2024 21:31:00 EEST | Business Wire | Press release
Today, NIKE, Inc. (NYSE: NKE) extended its position as the undisputed leader of footwear and apparel innovation by debuting a new line-up of products that signaled a multi-year innovation cycle. Brought to life by the full power of digital capabilities and cutting-edge technology, the company is delivering better, faster, more efficient solutions for athletes this summer and opening a world of creative possibilities — including Nike's first sculpted, visible Air Zoom unit in the new Pegasus Premium running shoe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411422311/en/
Harnessing its proprietary Air technology, Nike debuts the Nike Pegasus Premium – taking the cushioning that runners love from the iconic Pegasus franchise and adding Nike’s first sculpted, visible Air Zoom unit. The new, sculpted Air Zoom unit is the brand’s biggest Air innovation since the launch of the Nike Air VaporMax. (Photo: Business Wire)
The proprietary, sculpted Air unit connects the heel and forefoot and uniquely contours to the natural profile of the foot, delivering an entirely new springy, smooth sensation. Combined with ZoomX and ReactX foam, the new cushioning system creates more energy return for everyday runners.
In addition, Air, Nike’s most revolutionary, ubiquitous and versatile cushioning platform, powers the products Nike athletes will wear on the track, court and pitch this summer. Nike has optimized Air by leveraging computational design and incomparable athlete data from the Nike Sport Research Lab to create footwear that helps all athletes break barriers.
“For more than 50 years we’ve listened to and over-delivered for our athletes with the best of Nike innovation. We always push the boundaries of what’s possible and take risks to help create the future of sport together,” said John Hoke, Nike’s Chief Innovation Officer. “This summer, the difference maker is the massive energy return that Nike Air delivers to athletes. Taking what we learned from our super-shoe technology, we’re introducing new Nike Air Zoom shapes and sensations across all sports.”
The best of Nike’s Air innovation for this summer will debut in the Nike Blueprint Pack, spanning footwear for track and road racing, basketball, football, skate, breakdancing and lifestyle. The blue, white and orange colorway is a nod to Nike’s co-founder, Bill Bowerman, and his obsession with enabling the best-possible athlete performance.
Nike’s world-class athletes, including Dina Asher-Smith, Shelly-Ann Fraser-Pryce, Eliud Kipchoge and Sha’Carri Richardson, revealed the brand’s 2024 federation kits, which are the most data-driven and visually unified Nike’s ever produced. Based on 4D motion-capture data, with pixel-level precision and specifically designed for each competition, the kits were inspired by the distinct identities and diverse communities of each country and sport.
Nike also revealed A.I.R. — Athlete Imagined Revolution. In this co-creation project between elite athletes and Nike designers, Nike used innovative design tools to create the future of Air. The radical concepts are a view into the future of athlete co-creation, as well as the unlimited possibilities of Nike Air.
“There are now no limits to what we can create with Nike Air,” said Hoke. “We’re obsessing new technologies like AI engines and rapid prototyping to continue exploring the unlimited possibilities. Now we can create Nike products with unprecedented fidelity, velocity and impact.”
“We’re thrilled to celebrate another summer of sport with our incredible athletes and the product innovations that will help propel them to achieve their dreams,” said Heidi O’Neill, President, Consumer, Product and Brand, NIKE, Inc. “What you’ll see this year on the pitch, court, road or track signals a new, exciting multi-year cycle of innovation for us. And this summer is just a hint of the game-changing innovations coming across our entire portfolio that will take us into new markets and market share opportunities.”
NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available on the Internet at http://investors.nike.com. Individuals can also visit http://news.nike.com and follow @NIKE.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411422311/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
